Please check your internet connection and try again.
# Walethmade bromide
## Overview
**Note:** There is no clinical entity or FDA-approved medication known as "Walethmade bromide." This term appears to be a misspelling or non-existent in pharmaceutical databases (e.g., Lexicomp, Micromedex). If this refers to **Aclidinium bromide**, **Tiotropium bromide**, or another similar anticholinergic/bronchodilator, please verify the spelling.
*The information below reflects the profile of typical quaternary ammonium bromide compounds (e.g., anticholinergic bronchodilators such as Tiotropium).*
## Primary Indications
Maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema; off-label use for refractory asthma.
## Adult Dosing
* **Maintenance:** Typically 18 mcg inhaled once daily via specific dry powder inhaler (DPI) or 5 mcg once daily via mist inhaler.
* **Maximum Dose:** Do not exceed one dose per 24-hour period.
## Pediatric Dosing
Safety and efficacy have not been established in patients <18 years of age. Use is generally not recommended in the pediatric population.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required; however, monitor closely for anticholinergic side effects (e.g., urinary retention) in patients with moderate to severe impairment (CrCl <50 mL/min).
* **Hepatic Impairment:** No dose adjustment required.
## Contraindications
* Hypersensitivity to the drug or its components (e.g., milk proteins in certain DPI formulations).
* History of severe hypersensitivity to atropine or its derivatives.
* Acute treatment of bronchospasm (not a rescue inhaler).
## Adverse Effects
* **Common:** Xerostomia (dry mouth), upper respiratory tract infection, sinusitis, pharyngitis, cough.
* **Serious:** Paradoxical bronchospasm, urinary retention, narrow-angle glaucoma, tachycardia, blurred vision.
## Key Drug Interactions
* **Anticholinergics:** Concomitant use with other medications having anticholinergic properties (e.g., ipratropium, oxybutynin) increases the risk of additive adverse effects (e.g., constipation, urinary retention, cognitive impairment).
## Monitoring
* Monitor for paradoxical bronchospasm upon the first dose.
* Regular assessment of lung function (FEV1), symptom progression, and maintenance of oral hygiene (to mitigate dry mouth).
* Monitor for signs of urinary retention or ocular pressure issues in susceptible individuals.
## Clinical Pearls
* **Administration:** Ensure patient demonstrates proper inhaler technique; the medication provides no immediate relief for acute respiratory distress.
* **Storage:** Keep in a cool, dry place; avoid extreme humidity.
* **Verification:** Confirm that the drug name is spelled correctly, as errors in identifying bromide-based salts can lead to incorrect therapeutic selection (e.g., confusing bronchodilators with sedative medications like potassium bromide).
***
**Educational Disclaimer:** This information is for educational purposes only. The drug name provided does not exist in standard medical pharmacology databases. Always verify the medication name, indication, and dosing protocols against current institutional guidelines, the manufacturer's official package insert, and EHR-integrated clinical decision support tools before prescribing or administering medication.
